|
Cisplatin, Etoposide, and Radiation Therapy in Treating Patients With Limited-Stage Small Cell Lung Cancer Clinical Trials Facts presented on Clinical Trials Search is not designed to be a substitute for certified medical advice, travels to or professional assistance by using a genuine doctor. We aren't mDs. Always consult your physician about Cisplatin, Etoposide, and Radiation Therapy in Treating Patients With Limited-Stage Small Cell Lung Cancer conditions. Clinical Trials Search.org is a website committed to listing clinical research studies in human subjects. Cisplatin, Etoposide, and Radiation Therapy in Treating Patients With Limited-Stage Small Cell Lung Cancer Clinical research trials and Cisplatin, Etoposide, and Radiation Therapy in Treating Patients With Limited-Stage Small Cell Lung Cancer health trials occur in a lot of of cities throughout the US. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally evaluate the potency of new does drugs. The role of the studies / undertakings is to figure out specific human healthcare questions. Clinical trials are a popular manner for mDs, government agencies, and private sector companies to locate treatments for all sorts of conditions, including Cisplatin, Etoposide, and Radiation Therapy in Treating Patients With Limited-Stage Small Cell Lung Cancer. Cisplatin, Etoposide, and Radiation Therapy in Treating Patients With Limited-Stage Small Cell Lung Cancer Clinical Trials and other clinical trials permit volunteers to get medical treatment choices before they are available to the general public. Many times the test subjects get professional assistance for free of charge, and occasionally they are compensated for their time. Sometimes there is a cost for a Cisplatin, Etoposide, and Radiation Therapy in Treating Patients With Limited-Stage Small Cell Lung Cancer clinical trial. Human subjects often get the best healthcare possible for their Cisplatin, Etoposide, and Radiation Therapy in Treating Patients With Limited-Stage Small Cell Lung Cancer condition. Risks are a reality, nevertheless, and could include additional or frequent dr. calls, medical hazards (perhaps life-threatening), and/or the treatment being ineffectual. Trials are federally governed with exacting guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "C" Clinical Trials Conditions > Cisplatin, Etoposide, and Radiation Therapy in Treating Patients With Limited-Stage Small Cell Lung Cancer  Cisplatin, Etoposide, and Radiation Therapy in Treating Patients With Limited-Stage Small Cell Lung Cancer
Cisplatin, Etoposide, and Radiation Therapy in Treating Patients With Limited-Stage Small Cell Lung Cancer
For Condition: limited stage small cell lung cancer
Status: Recruiting
Sponsor(s): Radiation Therapy Oncology Group , National Cancer Institute (NCI)
Synopsis: RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Combining more than one chemotherapy drug with radiation therapy may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combining cisplatin and etoposide with radiation therapy in treating patients who have limited-stage small cell lung cancer.
Details: OBJECTIVES: - Determine the response rate of patients with limited stage small cell lung cancer treated with cisplatin and etoposide combined with accelerated high-dose thoracic radiotherapy. - Determine the progression-free and overall survival in patients treated with this regimen. - Determine the qualitative and quantitative toxicity and reversibility of toxicity of this regimen in these patients. OUTLINE: Patients undergo radiotherapy once daily 5 days a week for approximately 3 weeks and then twice daily 5 days a week for approximately 2 weeks. Beginning on the first day of radiotherapy, patients receive cisplatin IV over 2 hours and etoposide IV over 1 hour on day 1 and oral etoposide once daily on days 2 and 3. Chemotherapy repeats every 3 weeks for up to 4 courses in the absence of disease progression or unacceptable toxicity. Patients are followed every 3 months for 1 year, every 6 months for 2 years, and then annually thereafter. PROJECTED ACCRUAL: A total of 71 patients will be accrued for this study within 18 months.
Eligibility:
Study Type: Interventional, Treatment
Minimum Age/Maximum Age: 18 Years/
Genders: Both
Protocol Entry Criteria: DISEASE CHARACTERISTICS: - Histologically or cytologically confirmed small cell carcinoma of the lung by fine needle aspiration biopsy or two positive sputa - Must have limited disease - Stage I, II, IIIA, or IIIB - Confined to 1 hemithorax, but excluding the following: - T4 tumor based on malignant pleural effusion - N3 disease based on contralateral hilar or supraclavicular involvement - No pericardial or pleural effusions on chest x-ray (regardless of cytology) - Measurable or evaluable disease - Tumor must be able to be encompassed by limited radiotherapy fields without significantly compromising pulmonary function - No prior complete tumor resection PATIENT CHARACTERISTICS: Age - 18 to 100 Performance status - Zubrod 0-1 Life expectancy - Not specified Hematopoietic - Absolute granulocyte count at least 1,500/mm^3 - Platelet count at least 150,000/mm^3 Hepatic - Bilirubin no greater than 1.5 mg/dL Renal - Creatinine no greater than 1.5 mg/dL Cardiovascular - No myocardial infarction within the past 6 months - No symptomatic heart disease Pulmonary - No chronic obstructive pulmonary disease with FEV_1 no greater than 0.8 liter - No uncontrolled bronchospasm in the unaffected lung Other - Not pregnant or nursing - Negative pregnancy test - Fertile patients must use effective contraception - Available for follow-up - No other prior or concurrent malignancy except curatively treated basal cell or squamous cell skin cancer or non-invasive in situ malignancies - No other concurrent serious medical illness - No uncontrolled psychiatric illness - No chronic alcohol or drug abuse PRIOR CONCURRENT THERAPY: Biologic therapy - Not specified Chemotherapy - No prior chemotherapy Endocrine therapy - Not specified Radiotherapy - No prior radiotherapy to the chest or other area containing a large amount of bone marrow (e.g., more than 75% of pelvic bone) Surgery - See Disease Characteristics
Total Enrollment:
Location and Contact Information:
Overall Study Official:
RitsukoKomaki, Study Chair, M.D. Anderson Cancer Center
University of Alabama at Birmingham Comprehensive Cancer Center *Recruiting*
Birmingham, Alabama, 35294-3300
United States
Recruiting Ruby Meredith 205-934-4763
Lankenau Cancer Center at Lankenau Hospital *Recruiting*
Wynnewood, Pennsylvania, 19096
United States
Recruiting Contact Person 610-645-2680
St. Louis University Hospital Cancer Center *Recruiting*
St. Louis, Missouri, 63110-0250
United States
Recruiting Oscar Norton 314-577-8815
Fox Chase Cancer Center at St. Francis Medical Center *Recruiting*
Trenton, New Jersey, 08629
United States
Recruiting Jo Chalal 609-599-5179
Utah Valley Regional Medical Center - Provo *Recruiting*
Provo, Utah, 84604
United States
Recruiting Tarlton Blair 801-373-7850 ext. 2480
Miami Valley Hospital *Recruiting*
Dayton, Ohio, 45409
United States
Recruiting Contact Person 937-208-346
CCOP - Dayton *Recruiting*
Dayton, Ohio, 45429
United States
Recruiting Howard Gross 937-395-8678
Bryn Mawr Hospital *Recruiting*
Bryn Mawr, Pennsylvania, 19010
United States
Recruiting Contact Person 610-526-3686
Wendt Regional Cancer Center of Finley Hospital *Recruiting*
Dubuque, Iowa, 52001
United States
Recruiting Thomas Lally 319-589-2468
Good Samaritan Hospital *Recruiting*
Dayton, Ohio, 45406-1891
United States
Recruiting Contact Person 937-278-2612
Kettering Medical Center *Recruiting*
Kettering, Ohio, 45429
United States
Recruiting Contact Person 937-296-7246
CCOP - Bay Area Tumor Institute *Recruiting*
Oakland, California, 94609-3305
United States
Recruiting Brenda Shank 510-456-8570
CCOP - MainLine Health *Recruiting*
Wynnewood, Pennsylvania, 19096
United States
Recruiting Albert DeNittis 610-645-2433
LDS Hospital *Recruiting*
Salt Lake City, Utah, 84143
United States
Recruiting William Sause 801-408-1146
Paoli Memorial Hospital *Recruiting*
Paoli, Pennsylvania, 19301-1792
United States
Recruiting Contact Person 610-648-1637
Cottonwood Hospital Medical Center *Recruiting*
Murray, Utah, 84107
United States
Recruiting Contact Person 801-314-5300
McKay-Dee Hospital Center *Recruiting*
Ogden, Utah, 84403
United States
Recruiting Contact Person 801-627-2800
Foundation for Cancer Research and Education *Recruiting*
Phoenix, Arizona, 85013
United States
Recruiting David Brachman 602-274-4484
Dixie Regional Medical Center *Recruiting*
St. George, Utah, 84770
United States
Recruiting Ray Richards 801-688-4175
Grandview Hospital *Recruiting*
Dayton, Ohio, 45405
United States
Recruiting Contact Person 937-226-3200
Cancer Treatment Center *Recruiting*
Cincinnati, Ohio, 45206
United States
Recruiting Contact Person 513-569-6414
Cancer Care Center, Incorporated *Recruiting*
Salem, Ohio, 44460
United States
Recruiting Contact Person 330-375-3557
Greene Memorial Hospital *Recruiting*
Xenia, Ohio, 45385
United States
Recruiting Contact Person 937-226-3200
Akron City Hospital *Recruiting*
Akron, Ohio, 44304
United States
Recruiting William Demas 330-375-3557
West Michigan Cancer Center *Recruiting*
Kalamazoo, Michigan, 49007
United States
Recruiting Contact Person 616-373-7488
Middletown Regional Hospital *Recruiting*
Middletown, Ohio, 45044
United States
Recruiting Contact Person 513-424-2111
Methodist Hospital Cancer Center at Nebraska Methodist Hospital - Omaha *Recruiting*
Omaha, Nebraska, 68114-4199
United States
Recruiting James Wheeler 402-354-4104
CCOP - Marshfield Clinic Research Foundation *Recruiting*
Marshfield, Wisconsin, 54449
United States
Recruiting Tarit Banerjee 715-387-5134
Additional Information:
Study ID Numbers: CDR0000271939; RTOG-0239
Study Start Date:
Record last reviewed: August 2003
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00066222
Other Limited Stage Small Cell Lung Cancer Studies:
1. Cisplatin and Irinotecan Followed by Carboplatin, Etoposide, and Radiation Therapy in Treating Patients With Limited-Stage Small Cell Lung Cancer
2. Diagnosis and Treatment Planning in Patients Suspected of Having Lung Cancer
3. Captopril in Treating Patients With Non-Small Cell Lung Cancer or Limited-Stage Small Cell Lung Cancer That Has Been Previously Treated With Radiation Therapy With or Without Chemotherapy
4. Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Limited-stage Small Cell Lung Cancer
5. Combination Chemotherapy and Radiation Therapy in Treating Patients With Limited-Stage Small Cell Lung Cancer
Related Studies:
Other limited stage small cell lung cancer Clinical Trials
Other Utah Clinical Trials
Other Salt Lake City Clinical Trials
Cisplatin, Etoposide, and Radiation Therapy in Treating Patients With Limited-Stage Small Cell Lung Cancer
|
|
|
|
|
|
|
|
